Best Practice for Clinical Monitoring
Applied Clinical Trials
Our book review for the latest industry guidebook for monitors.
Author Gerald Van Roey has over 10 years of experience as a clinical monitor. His book offers sharp insights for both the new and experienced monitor.
After the first chapter primer about clinical research, Van Roey delves into the more granular areas of the practice of clinical monitoring. For that, the best chapter is Chapter 2. It looks at the qualities that make a good monitor and the relationship with an investigator.
Clinical Monitoring
Chapter 7 offers the reader a good grasp of initiation visits and tips on how to approach the study personnel.
Chapter 8, titled Monitoring Visits, is a large part of the book and takes on a lot. There is discussion about the import and export of clinical supplies, IMP distribution, tracking, and return of used IMP, which is very interesting and something with which I didn't have a lot of knowledge, and found very helpful.
Sections on site management, recruitment issues, the right protocol, and site selection included good information, but maybe not so related to the function of monitoring. Subject recruitment is a very complex area of clinical trials. It requires many initiatives that all fire on the same cylinders to ensure rapid and inclusive enrollment. The chapter offers several good ideas such as the monitor playing a part in communicating protocol information to the site, pinpointing problem areas, and suggesting solutions. But the section seems geared to the pharmaceutical company, or the CROs function.
Overall, the book is well written, with a pleasing design. It offers excellent tips, drawing these out in colored boxes to help the reader.
The book is available from the publisher PharmImage, www.PharmImage.com, and costs €39.95, or approximately $56.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
